Evaluation and Management of Elderly Patients With Lung Cancer

Hoffman, 2002, Evaluating and treating unintentional weight loss in the elderly, Am Fam Physician, 65, 640 Gill, 2004, Hospitalization, restricted activity, and the development of disability among older persons, JAMA, 292, 2115, 10.1001/jama.292.17.2115 Werner-Wasik, 2000, Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small cell lung cancer (LA-NSCLC): Identification of five groups with different survival, Int J Radiat Oncol Biol Phys, 48, 1475, 10.1016/S0360-3016(00)00801-4 Movsas, 1999, The benefit of treatment intensification is age and histology dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies, Int J Radiat Oncol Biol Phys, 45, 1143, 10.1016/S0360-3016(99)00325-9 Schild, 2003, The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly, J Clin Oncol, 21, 3201, 10.1200/JCO.2003.12.019 Langer, 2002, Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial, J Natl Cancer Inst, 94, 173, 10.1093/jnci/94.3.173 Janssen-Heijnen, 2004, Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer, Thorax, 59, 602, 10.1136/thx.2003.018044 Chrischilles, 2010, Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer, J Clin Oncol, 28, 620, 10.1200/JCO.2009.23.8485 Firat, 2006, Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC), Am J Clin Oncol, 29, 252, 10.1097/01.coc.0000217824.20290.ab Ramsey, 2004, Chemotherapy use, outcomes and costs for older persons with advanced non-small-cell lung cancer: Evidence from surveillance, epidemiology and end results-Medicare, J Clin Oncol, 22, 4971, 10.1200/JCO.2004.05.031 Wan-Chow-Wah, 2011, Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians, Crit Rev Oncol Hematol, 78, 45, 10.1016/j.critrevonc.2010.02.010 Asmis, 2008, Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of the National Cancer Institute of Canada Clinical Trials Group trials, J Clin Oncol, 26, 54, 10.1200/JCO.2007.12.8322 Birim, 2003, Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer, Eur J Cardiothorac Surg, 23, 30, 10.1016/S1010-7940(02)00721-2 Extermann, 1998, Comorbidity and functional status are independent in older cancer patients, J Clin Oncol, 16, 1582, 10.1200/JCO.1998.16.4.1582 Firat, 2002, Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer, Int J Radiat Oncol Biol Phys, 52, 1047, 10.1016/S0360-3016(01)02741-9 Firat, 2002, Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small cell lung cancer: An institutional analysis of patients treated on four RTOG studies, Int J Radiat Oncol Biol Phys, 54, 357, 10.1016/S0360-3016(02)02939-5 Colinet, 2005, A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: Description and comparison with the Charlson's index, Br J Cancer, 93, 1098, 10.1038/sj.bjc.6602836 Steensma, 2007, Anemia in the elderly: How should we define it, when does it matter, and what can be done?, Mayo Clin Proc, 82, 958, 10.4065/82.8.958 Langer, 2001, Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy?, Int J Radiat Oncol Biol Phys, 51, 20, 10.1016/S0360-3016(01)01860-0 Lee, 2011, Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review, J Clin Oncol, 29, 106, 10.1200/JCO.2010.31.3049 Kates, 2009, Validation of a model to predict perioperative mortality from lung cancer resection in the elderly, Am J Respir Crit Care Med, 179, 390, 10.1164/rccm.200808-1342OC Milroy, 2005, A pilot study of co-morbidity in newly diagnosed lung cancer patients, Lung Cancer, 49, 204, 10.1016/S0169-5002(05)80829-3 Grose, 2011, Comorbidity in lung cancer: Important but neglected, Clin Lung Cancer, 12, 207, 10.1016/j.cllc.2011.03.020 Extermann, 2012, Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-age patients (CRASH) score, Cancer, 118, 3377, 10.1002/cncr.26646 Owonikoko, 2007, Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database, J Clin Oncol, 25, 5570, 10.1200/JCO.2007.12.5435 Mery, 2005, Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database, Chest, 128, 237, 10.1378/chest.128.1.237 Yamamoto, 2003, Surgical results of stage I non-small cell lung cancer: Comparison between elderly and younger patients, Eur J Cardiothorax Surg, 23, 21, 10.1016/S1010-7940(02)00661-9 Sigel, 2009, Effect of age on survival of clinical stage I non-small-cell lung cancer, Ann Surg Oncol, 16, 1912, 10.1245/s10434-009-0475-8 Rivera, 2011, Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: A nested case-control study, Chest, 140, 874, 10.1378/chest.10-2841 Cerfolio, 2009, Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival, Eur J Cardiothorac Surg, 35, 718, 10.1016/j.ejcts.2008.12.029 Sullivan, 2005, Advanced age does note exclude lobectomy for non-small cell lung carcinoma, Chest, 128, 2671, 10.1378/chest.128.4.2671 Muraoka, 2005, Surgical treatment for lung cancer in octogenarians, Surg Today, 35, 725, 10.1007/s00595-005-3031-6 Haasbeek, 2010, Stage I nonsmall cell lung cancer in patients ages > or = 75 years: Outcomes after stereotactic radiotherapy, Cancer, 116, 406, 10.1002/cncr.24759 Raz, 2007, Natural history of stage I non-small cell lung cancer: Implications for early detection, Chest, 132, 193, 10.1378/chest.06-3096 Louie, 2011, Withholding stereotactic radiation therapy in elderly patients with stage I non-small cell lung cancer and coexisting COPD is not justified: Outcomes of a Markov model analysis, Radiother Oncol, 99, 161, 10.1016/j.radonc.2011.04.005 Parashar, 2011, Management of single malignant lung nodules in elderly patients (70 years or older) who are not candidates for lobectomy, Am J Clin Oncol, 10.1097/COC.0b013e31821a496d Palma, 2011, Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery, Radiother Oncol, 101, 240, 10.1016/j.radonc.2011.06.029 Pignon, 2008, Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group, J Clin Oncol, 26, 3552, 10.1200/JCO.2007.13.9030 Pepe, 2007, Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10, J Clin Oncol, 25, 1553, 10.1200/JCO.2006.09.5570 2000, Chemotherapy for non-small cell lung cancer, Cochrane Database Syst Rev Früh, 2008, Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer, J Clin Oncol, 26, 3573, 10.1200/JCO.2008.16.2727 Kharofa, 2012, Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy, Int J Radiat Oncol Biol Phys, 10.1016/j.ijrobp.2011.11.013 Pignon, 1998, Age has no impact on acute and late toxicity of curative thoracic radiotherapy, Radiother Oncol, 46, 239, 10.1016/S0167-8140(97)00188-6 Nguyen, 1999, Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: A retrospective review, Int J Radiat Oncol Biol Phys, 44, 1053, 10.1016/S0360-3016(99)00130-3 Gore, 2011, Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients with locally advanced non-small cell lung cancer [LA-NSCLC]: Radiation Therapy Oncology Group (RTOG) 0213, Clin Lung Cancer, 12, 125, 10.1016/j.cllc.2011.03.007 Gore, 2011, Pulmonary resection after high dose radiation therapy (>59 Gy) and concurrent chemotherapy for non-small cell lung cancer, J Thorac Oncol, 6, 1558 Albain, 2009, Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial, Lancet, 374, 379, 10.1016/S0140-6736(09)60737-6 Fairchild, 2009, International patterns of practice in palliative radiotherapy for painful bone metastases: Evidence-based practice?, Int J Radiat Oncol Biol Phys, 75, 1501, 10.1016/j.ijrobp.2008.12.084 Sundstrøm, 2004, Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: A national phase III trial, J Clin Oncol, 22, 801, 10.1200/JCO.2004.06.123 1999, Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer, J Natl Cancer Inst, 91, 66, 10.1093/jnci/91.1.66 Kudoh, 2006, Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904), J Clin Oncol, 24, 3657, 10.1200/JCO.2006.06.1044 Belani, 2005, Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326), Cancer, 104, 2766, 10.1002/cncr.21495 Ansari, 2011, A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer, Crit Rev Oncol Hematol, 78, 162, 10.1016/j.critrevonc.2010.03.003 Lilenbaum, 2005, Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730), J Clin Oncol, 23, 190, 10.1200/JCO.2005.07.172 Blanchard, 2011, Comparison of platinum-based chemotherapy in patients older and younger than 70 years: An analysis of Southwest Oncology Group Trials 9308 and 9509, J Thorac Oncol, 6, 115, 10.1097/JTO.0b013e3181fbebfd Frasci, 2000, Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer, J Clin Oncol, 18, 2529, 10.1200/JCO.2000.18.13.2529 Gridelli, 2003, Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial, J Natl Cancer Inst, 95, 362, 10.1093/jnci/95.5.362 Quoix, 2011, Intergroupe Francophone de Cancérologie Thoracique, Lancet, 378, 1079, 10.1016/S0140-6736(11)60780-0 Hesketh, 2007, Chemotherapy in patients > 80 with advanced non-small cell lung cancer: Combined results from SOWG 0027 and LUN 6, J Thorac Oncol, 2, 494, 10.1097/JTO.0b013e318060097e Ramalingam, 2008, Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599, J Clin Oncol, 26, 60, 10.1200/JCO.2007.13.1144 Wakelee, 2008, Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperate Oncology Group (ECOG) E4599, J Thorac Oncol, 3, S282 Reck, 2009, Phase III trial of cisplatin plus gemcitabin with either placebo or bevacizumab as first-lin therapy for non-squamous non-small-cell lung cancer: AVAiL, J Clin Oncol, 27, 1227, 10.1200/JCO.2007.14.5466 Leighl, 2010, Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsqamous non-small cell lung cancer in the phase III BO17704 study (AVAiL), J Thorac Oncol, 5, 1970, 10.1097/JTO.0b013e3181f49c22 Jackman, 2007, Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer, J Clin Oncol, 25, 760, 10.1200/JCO.2006.07.5754 Wheatley-Price, 2008, Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21, J Clin Oncol, 26, 2350, 10.1200/JCO.2007.15.2280 Crinò, 2008, Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study, J Clin Oncol, 26, 4253, 10.1200/JCO.2007.15.0672 Sasaki, 2011, New strategies for treatment of ALK rearranged non-small cell lung cancers, Clin Cancer Res, 17, 7213, 10.1158/1078-0432.CCR-11-1404 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 Gridelli, 2010, Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials, Lung Cancer, 67, 86, 10.1016/j.lungcan.2009.03.021 Gridelli, 2011, Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study, Ann Oncol, 22, 1528, 10.1093/annonc/mdq630